MetaCap

Artelo Biosciences (ARTL) vs Lisata Therapeutics (LSTA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Artelo Biosciences is the larger company by market cap ($1.3 million vs $647,451), about 2.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ARTL-59.24%LSTA-23.17%
+13%-25%-63%
Oct 7, 20261 yearNov 20, 2026
ARTL-57.36%LSTA-15.20%
+18%-22%-61%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ARTL versus LSTA key metrics
MetricARTLLSTA
Share price$1.39$0.8989
Market cap$1.30M$647.45K
1-day change-4.14%-1.22%
YTD return—-51.67%
1-year return—-54.14%
5-year return—-93.89%
EPS (TTM)$-20.56$-28.20
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$170.00K
Revenue growth (YoY)—-83.00%
Net income (latest FY)$-12.88M$-16.59M
Operating margin—-10711.18%
Net margin—-9756.47%
52-week high$179.19$76.05
52-week low$1.30$0.85
Distance from 52-week high-99.22%-98.82%
Analyst consensus—none
Average volume476.69K13.46K
Shares outstanding937.18K720.27K
Employees721
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Artelo Biosciences is about 2.0 times larger than Lisata Therapeutics by market value ($1.30M vs $647.45K).

About Artelo Biosciences

ARTL stock →

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

About Lisata Therapeutics

LSTA stock →

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens.

Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees

ARTL vs LSTA FAQ

Which is bigger, Artelo Biosciences or Lisata Therapeutics?

Artelo Biosciences (ARTL) is larger, with a market capitalization of $1.30M compared with $647.45K for Lisata Therapeutics (LSTA).

Are Artelo Biosciences and Lisata Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons